Introduction
Natural products and their derivatives provide a significant number of new chemical leads for drug discovery programmes within a wide range of clinical areas 1 . For example, analysis of plant-based compounds has highlighted many potential clinical applications for flavonoids 2 . Within the area of flavonoids as anticancer agents [3] [4] [5] [6] [7] [8] [9] [10] [11] , the success of such approaches has been exemplified through the development of flavone derivatives such as flavopiridol (for chronic lymphocytic leukemia) 12, 13, 14 , silibinin (for prostate cancer) 15 , and quercetin 16 and its derivative QC12 17 (for ovarian cancer), which are at various stages of clinical application. Although the natural flavonoids demonstrate anti-proliferative activities and can themselves act as useful leads, these activities have often been reported at pharmacologically nonachievable high micromolar concentrations (50-100 µM) [18] [19] [20] [21] . Therefore, medicinal chemistry strategies are these compounds, in order to ensure that the full clinical applications for flavonoids are realised. In this study, we have proposed methylation of hydroxyls, and conversion of 4-C=O to 4-C=S, as a promising strategy to improve the activities of flavonoids, since these structural motifs could lead to flavonoids with desirable physiochemical properties such as increased lipophilicity and metabolic stability. Therefore, the aim of this study was to study the effects of methylation of free hydroxyls and 4-C=S substitution on the antiproliferative properties of the flavonoids by undertaking the systematic design, synthesis and biological analysis of a well-defined library of hydroxy flavone analogues. In addition, synthesis of this library of compounds would also allow structure-activity relationships (SARs) to be determined. This is of particular importance for flavonoids as in-depth understanding of the SARs for anticancer properties of flavones is still limited 22, 23 . Specifically, the significance of some of their core structural features for activity, such as hydroxyl substitutions at different positions on the flavonoid rings, and the effect of methylation of the free hydroxyls on activity, are poorly defined. Also, the impact of modifying the 4-C=O substituent on the anticancer activities of flavones has not been extensively studied.
Results and discussion

Design and Synthesis
To realise the aims of this study, structurally related hydroxy and methoxy flavones, and their 4-thio derivatives, were synthesised. The synthesis of the methoxy and hydroxy flavone scaffolds was achieved using a synthetic strategy involving the BakerVenkataraman rearrangement as a key step (Scheme-1). 24, 25 The 4-thio analogues were obtained according to Scheme-2 26 in 20-30% overall yield (see experimental section in supporting information material for full details).
First, the effects of methylation and 4-thio modifications on flavones with different numbers of hydroxyl groups and different positions of hydroxyls on ring-A, were investigated. Thus, 20 flavones comprising of i) dihydroxy flavones with hydroxyl substitution on ring-A at the C-7,8 or C-5,7 positions, ii) tetrahydroxy flavones with dihydroxyl substitution on ring-A (at the C-7,8 or C-5,7 positions) and on ring-B (at the C-3'and C-4' positions), and iii) pentahydroxy flavones with dihydroxyl substitution on ring-A (at the C-5,7 position only) and on ring-B (at the C-3'and C-4' positions) as well as a hydroxyl group at the C-3 position on ring-C were designed and synthesised.
The analogous methoxy and 4-thio derivatives were also prepared (compounds-1c-f to 5c-f, Series-1, Figure-1 ).
The pentahydroxy flavone (quercetin) derivatives (5c-f) were obtained starting from pentahydroxy flavone (purchased) according to Scheme-3 27, 28 in 36% overall yield and with 99% purity by HPLC. This represents an improvement on the recently reported synthesis of 5f, both in terms of overall yield and purity 29 (22% overall yield and 95% purity). The panel of flavones studied herein also contained the well-known natural flavones chrysin (2d), luteolin (4d) and quercetin (5d) to allow comparisons to be made between the novel analogues prepared in our laboratory and some standard flavonoids. The design of further series of flavones was guided by the anti-proliferative activities of Series-1 compounds. Therefore, compound-2f, a dihydroxy 4-thio flavone that was identified to possess promising anti-proliferative activity in in vitro screening (discussed below), was considered as a candidate for further optimisation through the bioisostere approach and Topliss scheme 30 . This resulted in the synthesis of a focused set of dihydroxy flavone analogues (bearing C-7,8 and C-5,7 hydroxyls on ring-A) with phenyl bioisosteres (Series-2, Figure-1 ), and phenyl groups with electron-withdrawing substituents at the C-4' position (based on the Topliss scheme for the optimisation of phenyl ring substitution in drug design 30 ) (Series-3, Figure-1 
Anti-proliferative evaluation
As flavonoids have been reported to show activity against breast cancer cell lines [32] [33] [34] , all of the synthesised compounds (1c-f to 19c-f) were evaluated for their anti-proliferative activity against the estrogen- 35, 36 . In general, all compounds exhibited a 3-10 fold lower anti-proliferative activity against MCF-7/DX, which could be because these compounds might act as substrates of the efflux pump P-gp, which is generally over expressed in the MCF-7/DX cell line 37 .
Next, Series 1 compounds (1c-f to 5c-f) were assessed for their anti-proliferative activities at 10 µM concentration against an ER-ve hormone-independent breast cancer cell line, MDA-MB-231. The 4-thio derivatives, and in particular the hydroxy compounds, exhibited greater anti-proliferative activity than the methoxy and hydroxy flavone analogues. However, no derivatives reached the IC 50 at 10 µM (See supporting information, Figure-S1 ).
As compound-2f was identified as a promising lead compound, further novel analogues of compound-2f were prepared to discover more active flavone derivatives. Thus a series of bioisosteric analogues of the B-ring phenyl group of compound-2f (Series-2, compounds 6c-f to 11c-f), and a series of compound-2f analogues with electron-withdrawing substituents at the C4'position (Series-3, compounds 12c-f to 19c-f), along with their methoxy (both 4-C=O and 4-C=S) and their 7,8- regioisomeric analogues (both 4-C=O and 4-C=S), were synthesised and evaluated for their anti-proliferative activities. Since compound-2f was identified to be active below 10 µM and 50 µM against MCF-7 and MCF-7/DX, respectively, these subsequently synthesised compounds were initially assessed for their anti-proliferative activities at 10 µM concentration against the MCF-7 and MDA-MB-231 cell lines, and at 50 µM against the MCF-7/DX cell line. Compounds that reduced the cell viability below 50% in the initial screening were arbitrarily classified as 'active' and they were then evaluated at a range of concentrations In the initial screening, Series-2 compounds with bioisosteric replacements showed a decreased/complete loss of activity with cell viability > 50% (See supporting information, Figure-S2 ). Among Series-3, the novel compounds 14f and 16f were found to be active against all three cell lines, and novel compounds 13f, 15f, 17f and 19f were found to be active against both the MCF-7 and MCF-7/DX cell lines. Novel compounds 12f and 18f were found to be active only against the MCF-7 cell line ( Figure-2 ). These active compounds were further tested against the respective cell lines at different concentrations ranging from 0.1 to 100 µM to determine their IC 50 values. The determined IC 50 values are listed in Table- 2. Among these, novel compounds 15f (IC 50 = 1.0 ± 0.1 µM and 9.1 ± 0.1 µM against MCF-7 and MCF-7/DX cell lines respectively) and 16f (IC 50 = 4.9 ± 0.7 µM, 6.5 ± 0.4 µM and 8.9 ± 0.9 µM against MCF-7, MCF-7/DX and MDA-MB-231 cell lines respectively) were identified as active compounds. Note: Most active compounds of the series are highlighted in bold. Data represented is mean ± SEM, n=3. Log P values were determined using ChemDraw ultra 12.1 software.
The importance of free hydroxyls for anti-proliferative activity has previously been debated in the literature, with contradicting results. Thus, the results from our 41 and melanoma cell lines 19 .
Further, from the comparison of anti-proliferative activities between the hydroxy flavones (free -OH and 4-C=O) and their 4-thio analogues (free -OH and 4-C=S), it was apparent that the substitution of 4-C=S for 4-C=O enhances the anti-proliferative activity [compound-2f (free -OH and 4-C=S), IC 50 = 7.9 ± 0.8 µM < compound2d (free -OH and 4-C=O), IC 50 = 25.6 ± 1. Effect of bioisosteric replacements: Replacement of the B-ring phenyl group with a bioisostere (eg either a five-membered 2-thienyl, a 2-furanyl group, or a sixmembered 3-pyridyl group) resulted in a significant loss of anti-proliferative activity. This highlighted that the presence of a phenyl group as ring-B is favourable for anti-proliferative activity. Influence of electron-withdrawing groups: Interestingly, introduction of EWGs at the C4' position of the phenyl group, mainly with halogens such as F (12f and 13f), Cl (14f and 15f) and Br (16f and 17f) was found to enhance anti-proliferative activities in comparison to the flavones with an unsubstituted phenyl B-ring (compounds 1f and 2f). In particular, the introduction of Cl and Br groups increased the antiproliferative potencies 2-7 fold (14f, 15f, 16f and 17f) against MCF-7 and MCF-7/DX cell lines, and also their introduction afforded 7,8-dihydroxy 4-thioflavones with an increased anti-proliferative activity towards MDA-MB-231 cells (compound-1f: cell viability at 10 µM was 79%, whereas, compound-14f (containing -Cl) and compound-16f (containing -Br) showed 49% and 20% cell viability at 10 µM against MDA-MB-231). The pronounced activity observed for the -F, -Cl and -Br substituted 4-thioflavones could be attributed to their increased lipophilicity, as can be observed by the decrease in IC 50 values (more active) for increasing theoretical Log P values (Table-2) . A summary of SARs for the anti-proliferative activities of flavones analysed herein is depicted in Figure-3 . . This indicates that the majority of the flavonoid derivatives mediate their anti-proliferative effects via estrogen-independent mechanisms. A similar observation has been reported for 5-aminoflavones, which showed remarkable antiproliferative activity against the ER+ve MCF-7 cell line without ER competition, as determined by the ER binding assay 46 .
To confirm this finding, an ERα antagonism assay was carried out using the human estrogen receptor alpha assay kit which consists of ERα reporter cells in which an ERα-responsive promoter is functionally linked to the luciferase reporter gene, and allows quantification of changes in the ERα activity via measurement of the changes in luciferase expression. In order to evaluate whether the flavone derivatives mediate their antiproliferative effects via antagonism of ERα, compound15f (IC 50 = 1 µM) compound-16f (IC 50 = 4.9 µM) and compound-3e (IC 50 = 11.8 ± 1.79 µM), that were potent against MCF-7 cells, were assessed for their antagonist activity at four-point concentrations (10 µM -0.1 µM) in the presence of a constant concentration of 17β-estradiol (3.2 nM, EC 75 ). The known antagonist fulvestrant was used as a positive control. Compounds 15f and 16f did not show any decrease in the luciferase activity (induced by 17β-estradiol), which was in contrast to fulvestrant. However, compound-3e showed a dose-dependent decrease in the luciferase activity [see supporting information ( Figure-S4) for details]. These results support the findings from the in silico study that the majority of these compounds (except compound-3e) most likely act through an estrogen-independent mechanism.
b) Interactions with cell signalling proteins: Next, the signals mediated by compounds 15f and 16f in ER+ve MCF-7 and MCF-7/DX cells and ER-ve MDA-MB-231 cells were examined using the PathScan ® Intracellular
Signalling Array Kit, which allows simultaneous detection of 18 significant and well-characterised signalling molecules that undergo covalent posttranslational modifications, such as phosphorylation and proteolysis (cleavage). Protein samples obtained from the treatment of MCF-7, MCF-7/DX and MDA-MB-231 cells with compounds 15f (IC 50 < 10 µM against MCF-7 and MCF-7/DX) and 16f (IC 50 < 10 µM against MCF-7, MCF-7/DX and MDA-MB-231 cells) were analysed (Figure-4) . The results showed that the antiproliferative effects were mediated by significant inhibition of the Akt associated downstream target GSK-3β, which is a key signalling molecule for cell survival and proliferation. In addition, compound-15f, which showed greater potency towards MCF-7 cells (IC 50 = 1 µM for 15f vs IC 50 = 4.9 µM for 16f), was found to trigger cell death through PARP cleavage, which is a hallmark of the cell death pathway 47 . This explains the greater potency of compound-15f towards MCF-7 cells. It is noteworthy that no caspase-3 cleavage was observed; this suggests that the observed PARP cleavage is caspase-3 independent and the activation of 48 In the case of MCF-7/DX cells, compound-16f, that has greater activity towards MCF-7/DX cells than compound-15f, mediated its anti-proliferative effects through a significant reduction in the phosphorylation of several cell survival proteins such as mTOR, GSK-3β and Stat3, along with induction of cell death through caspase-3 and PARP cleavage. However, compound-15f was found to elicit its anti-proliferative effects through a reduction in the phosphorylation of GSK-3β as well as through induction of cell death via PARP cleavage. Thus, the higher potency of compound-16f could be related to its ability to downregulate multiple cell survival proteins (mTOR, GSK-3β and Stat3) along with its ability to induce cell death via caspase-3 and PARP cleavage.
Interestingly, treatment of MDA-MB-231 cells with compound-16f showed a 2-fold increase in the levels of p53 compared to the control. MDA-MB-231 cells have a mutant p53 gene 49, 50 that is more stable and oncogenic unlike the wild type p53 in MCF-7 cells 51 . The presence of mutant p53 drives the invasiveness of the tumour 52, 53 . However, the increase in the Serine-15 phosphorylated p53 (mutant) in compound-16f treated MDA-MB-231 cells [than the control (untreated)] linked with its profound activity suggest that compound-16f induces Ser-15 phosphorylation of a mutant p53 in MDA-MB-231 cells, which probably leads to the restoration of wild-type p53 DNA binding activity and induction of cell death. A similar observation has been reported for resveratrol (a chalcone) wherein cell death was induced by restoring the wild-type p53 DNA binding activity via the phosphorylation of a mutant p53 at Serine-15 in prostate cancer DU145 cells [54] [55] [56] .
This might explain the higher activity of compound-16f against MDA-MB-231 cells (IC 50 = 8.9 µM for 16f vs IC 50 > 10 µM for 15f).
Overall, these results correlate well with the in vitro findings, and suggest that for the MCF-7 and MCF-7/DX cell lines, the anti-proliferative effects are mediated via ER-independent cleavage of PARP and downregulation of GSK-3β. For the MDA-MB-231 cell line, activity could be due to restoration of the wild-type p53 DNA binding activity of the mutant p53 tumour suppressor gene. 
Apoptosis determination:
As compounds 15f and 16f were found to act via induction of the apoptotic signalling pathway (PARP, caspase-3 and p53), these compounds were further assessed for their ability to induce apoptosis. For this, MCF-7 and MDA-MB-231 cells were treated (at their IC 50 concentration for 24 h) with compounds 15f (1 µM and 10 µM against MCF-7 and MDA-MB-231, respectively) or 16f (5 µM and 9 µM against MCF-7 and MDA-MB-231, respectively) and were analysed for phosphatidylserine externalization (apoptosis marker) 57, 58 using an annexin V-FITC/propidium iodide (PI) apoptosis detection assay and flow cytometry. As shown in Figure-5 , a significant increase in the percentage of apoptotic cells in comparison to the untreated control was observed in the MCF-7 cells treated with either 15f or 16f, and in the MDA-MB-231 cells treated with 16f. These results clearly indicate that the flavones 15f and 16f potentially induce apoptosis in the MCF-7 and MDA-MB-231 cells, whilst only 16f potentially induces apoptosis in MDA-MB-231 cells. These observations are in line with the cytotoxicity data/protein array data. Therefore, from the molecular mechanism of action studies, and the apoptotic assay, for compounds 15f and 16f it can be concluded that these compounds induce apoptotic cell death via PARP cleavage in MCF-7 cells, and 16f triggers apoptosis by p53 induction in the MDA-MB-231 cell line. Please do not adjust margins
Please do not adjust margins 231 cells with compounds 15f and 16f. Data are expressed as mean± standard error of the mean (SEM), n = 3. Statistical significance was estimated with respect to the control (untreated sample) by one-way ANOVA, followed by Bonferroni's post hoc test (ns = nonsignificant; *, p < 0.05, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001).
NCI 60 cell line screening: Finally, to further probe the promising and significant anti-proliferative activities of the novel flavonoids 15f and 16f, they were screened for in vitro cytotoxicity by the National Cancer Institute Developmental Therapeutic Program 59 , USA (NCI/DTP, USA). Initial evaluation was performed at a single dose of 10 µM against 60 different human tumour cell lines using the Sulforhodamine B cytotoxic assay. 60 Both compounds showed potential growth inhibition against a wide range of cancer cell lines (See Supporting information Information). As a result, they were selected for further 5-dose assay screening against the 60 cell lines (0.01 µM -100 µM). Three end points, specifically the GI 50 (concentration that causes 50% growth inhibition), TGI (total growth inhibition) and LC 50 (the concentration of the drug at which the original cell number is reduced by 50%) were determined. The mean inhibitory doses (MID) against 60 cell lines for compound-15f and compound-16f were 2.81 µM and 2.39 µM respectively. The GI 50 values determined for these two compounds against 60 cell lines are presented in Table- 3. Interestingly, both compounds 15f and 16f exhibited nanomolar range activity various cell lines. Specifically, compound-15f showed the highest cytotoxicity against the breast cancer cell lines MCF-7 (GI 50 = 0.18 µM), T-47D (GI 50 = 0.03 µM) and MDA-MB-468 (GI 50 = 0.47 µM), HCT-15 (colon cancer, GI 50 = 0.48 µM), OVCAR-4 (ovarian, GI 50 = 0.57 µM). Also, compound-16f, showed significant cytotoxicity against NCI-H460 (NSCLC, GI 50 = 0.97 µM) and HCT-15 (colon cancer, GI 50 = 0.85 µM). The cytotoxicity profile of the well-known flavone chrysin (2d) [NSC407436] was retrieved from the NCI database (mean dose graph provided in supporting information) for comparison. Overall, compounds-15f and 16f were found to be 7-8 fold more potent than chrysin (MID-20.10 µM, against 51 cell lines). In particular, compounds-15f and 16f were found to be 46 fold and 13 fold more active than chrysin against an ovarian OVCAR-4 cell line, 43 fold and 24 fold more active than chrysin against colon HCT-15 and 5 fold and 15 fold more active than chrysin against the NSCLC NCI-H460 cell line, respectively (Figure-6 ). 
Conclusions
A library of 76 compounds containing structurally related methoxy and hydroxy flavones, and their 4-thio analogues, has been designed, synthesised and evaluated for anti-proliferative activity against the breast cancer cell lines MCF-7 (ER+ve), MCF-7/DX (ER+ve, anthracyline resistant) and MDA-MB-231 (ERve) . Within this library, 42 compounds were prepared and characterised for the first time within our laboratory. The study provided significant insight into the structural features required for enhancing the antiproliferative profiles of flavones, and identified two novel hydroxy 4-thioflavones 15f and 16f, as lead antiproliferative agents (15f (IC 50 = 1.0 ± 0.1 µM and 9. ± 0.1 µM against MCF-7 and MCF-7/DX cell lines, respectively) and 16f (IC 50 = 4.9 ± 0.7 µM, 6.5 ± 0.4 µM and 8.9 ± 0.8 µM against MCF-7, MCF-7/DX and MDA-MB-231 cell lines, respectively)). A systematic SAR study highlighted the presence of free hydroxyl groups, and the B-ring phenyl groups, as essential for enhanced anti-proliferative activities. Replacement of the 4-C=O functional group with the 4-C=S functional group also enhanced the anti-proliferative activities. Incorporation of lipophilic electron withdrawing groups at C4' of the B-ring phenyl was found to be favourable, and the increased lipophilicity correlates well with the greater anti-proliferative activities. Molecular mechanistic studies have suggested that the anti-proliferative effects of flavones 15f and 16f are mediated via ERindependent cleavage of PARP and downregulation of GSK-3β in the case of MCF-7 and MCF-7/DX cell lines. For the MDA-MB-231 cell line, a probable restoration of the wild-type p53 DNA binding activity of mutant p53 tumour suppressor gene was indicated. Taken together, these results demonstrate that the novel thioflavones 15f and 16f offer considerable potential as anti-proliferative agents within medicinal chemistry programmes focussed on cancer. In addition, the SARs derived herein are likely to contribute significantly to the design and synthesis of novel thioflavones for further therapeutic applications.
Experimental Materials and methods
Cell line and culture: MCF-7 (ER +ve breast cancer cell line) was provided by Tenovus Centre for Cancer Research (Cardiff, UK), MCF-7/DX (a doxorubicin resistant phenotype of MCF-7) was obtained as a gift from Professor Luigi Quintieri from the University of Padova, Italy and MDA-MB-231 (ER -ve breast cancer cell line) were purchased as a frozen stock from the European Collection of Cell Cultures (ECACC). MCF-7 and MCF-7/DX cells were cultured in RPMI 1640 supplemented with 5% fetal bovine serum, MDA-MB-231 cells were cultured in DMEM supplemented with 10% fetal bovine serum. All of the cell culture reagents were obtained from Lonza, UK. The PathScan Intracellular Signalling array kit was purchased from Cell Signaling (Catalog number-7323). ERα receptor anatagonist kit was purchased from Indigo biosciences, USA. Annexin V/propidium iodide apoptosis detection kit I was procured from BD, Pharmingen™, UK. For the cell culture experiments, the stock solutions of the test compounds (10 mg/mL) were prepared in sterile DMSO and ethanol (1:1 v/v) and these stocks were then appropriately diluted with the complete culture medium and, the ethanol and DMSO levels were maintained below 1% in the test concentrations. The IC 50 values were calculated using MS excel 2010. Molecular docking was performed using SYBYL-X-2.1 software.
Synthesis: See the supporting information.
Anti-proliferative assay: Anti-proliferative activities of the compounds were assessed using the MTT assay at 72 h of treatment. 
Molecular docking Docking validation:
To validate the accuracy of the docking procedure to be used, the original ligands were extracted from the coordinate files (taken from the Protein Data Bank PDB), and then docked again into the corresponding crystal structure of the proteins, using the automated docking procedure in the program Surflex-Dock (SFXC) 62, 63 , as provided by SYBYL-X-2.1.
The resulting ligand conformation from the docking procedure was compared with the ligand conformation as found in the actual crystal structure of the complex.
Comparative structural orientation of the ligand was calculated as the root mean square deviation (RSMD) between the docked ligand and the ligand as found in the crystal structure, using the programme LSQKAB, as provided in the CCP4 64 suite. If the root mean square deviation (RMSD) value between the real and the bestscored conformations is equal to or less than 2.0 Å (representing the grid spacing used for the docking procedure), then the docking process was considered successful 65 . In this case the docking procedure was first validated by re-docking the extracted cocrystallised ligand of human estrogen receptor-α (ERα) (2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-1,2,3,4-tetrahydro-isoquinolin-6-ol) into the prepared target protein to be used for docking. The RMSD between the docked conformation, as generated by the docking algorithm and the native co-crystallised ligand conformation was found to be 0.12 Å, which was well within the 2 Å grid spacing used in the docking procedure, indicating that the docking method to be used was reliable and valid. Furthermore, the interactions between the docked ligand and the prepared target receptor mimicked those observed in the crystal structure of the same.
Docking procedure: Docking studies were performed using the programme Surflex-Dock (SFXC) 62 as provided by Sybyl-X 2.1. The X-ray crystallographic structures of human estrogen receptor-α (ERα) complexed with an antagonist 2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-Protein Data Bank. The protein structure was prepared for docking using the Biopolymer Structure Preparation Tool with the implemented default settings provided in the SYBYL programme suite. Hydrogens were added to the protein structures in idealised geometries and an overall energy minimisation of each protein was performed using the MMFF94 force field, employing a conjugate gradient algorithm 66 with a convergence criterion of 0.5 kcal/mol A −1 and up to 5000 iterations.
Finally, before the docking run, all water molecules were removed and the ligand 2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-1,2,3,4-tetrahydroisoquinolin-6-ol was extracted from the coordinate file of the ER α (PDB-1UOM). The protomol, representing the ligand binding groove, was generated using a ligand directed method, which allows the docking of ligands into predefined sites, as defined by occupancy of any co-crystallised ligand at the site of interest.
The Surflex-X docking algorithm docks a given ligand to a receptor using a flexible ligand and a semi-flexible receptor; in this case the peptides were allowed to be fully flexible while the receptor was semi-flexible. This approach allows for optimisation of potentially favourable molecular interactions, such as those defined by hydrogen bond and van der Waal forces. The docking results yield a docking score, which takes into consideration entropic, polar, hydrophobic, repulsive and desolvation factors. Here, the docking scores were The docking results were visualised using the programme PyMOL 67,68 and the molecular interactions of the docked ligands were analysed by the programme CONTACTS, as provided in the CCP4 suite of programmes 64, 69, 70 . Potential hydrogen bonds were assigned if the distance between two electronegative atoms was less than 3.3 Å, whereas any separation greater than 3.3 Å, but less than 4.5 Å, was considered a van der Waal interaction. ERα antagonist assay: ERα reporter cells consisting of an ERα-responsive promoter gene functionally linked to the luciferase gene were defrosted and seeded into a 96-well plate and these cells were immediately dosed with the test compounds at different concentrations (10-0.1 µM) and with 17β estradiol (3.2 nM, EC 75 concentration) according to the manufacturer's protocol. After 24 h incubation in the presence of the test compound or solvent (DMSO), the cell viability of these treated/untreated reporter cells was measured to eliminate false positives using the fluorescencebased live cell multiplex (LCM) assay. The fluorescence from the live cells was measured using the plate reader with the filter combination of [485nmEx | 535nmEm]. Following this, fold reduction in the luciferase intensity, which is the measure of the antagonist activity was measured by using a luminometer (TECAN) according to the manufacturer's protocol. The data are expressed as the fold reduction as compared to the control. The mean of three experiments and the standard error is reported.
PathScan sandwich immunoassay:
The PathScan Intracellular Signalling array kit was used for the simultaneous detection of 18 significant and wellcharacterised cellular proteins and signalling nodes that were phosphorylated or cleaved at the specific residues.
Preparation of cell lysate: MCF-7 and MCF-7/DX cells (8  x 10 4 cell/mL) and MDA-MB-231 cells (4 x 10 4 cells/mL)
were seeded into 24 well plates (2 mL/well) and incubated for 24 h. After 24 h, the cells were treated with the test compounds at 10 µM concentration for 24 h. Following this 24 h exposure, the cells were washed with ice-cold 1X phosphate-buffered saline and lysed in 1X cell lysis buffer provided (phosphotase and protease inhibitors added). These lysates were quantified using the BCA protein assay.
for 15 min at room temperature. Subsequently, the cell lysate, diluted to 0.3 mg/mL in array diluents, was added to each well and incubated for 2 h at room temperature. Subsequent to washing, the detection antibody cocktail was added to each well and incubated for 1 h at room temperature. Horseradish peroxidase (HRP)-linked streptavidin was added to each well and incubated for 30 min at room temperature. The slide was then covered with LumiGLO/Peroxide reagent (Cell Signaling Technology) and exposed to film for 2-30 sec. The image was captured by a digital imaging system, ImageQuant LAS 4000 (GE Healthcare).
Apoptosis detection assay: Apoptosis in MCF-7 and MDA-MB-231 cells was assayed by annexin V and propidium iodide (PI) co-staining using an Annexin-V-FITC staining kit according to the manufacturer's instruction. 1 x 10 6 MCF-7 and MDA-MB-231 cells were plated into a 6 well plate (3.4 x 10 5 cells/ mL, 3 mL/well). After 24 h incubation, cells were treated without and with test compounds (at their IC 50 concentration) for 24 h. Cells were harvested using Accutase™ Cell Detachment Solution (1 mL/well) for 5 min at 37 ºC. Accutase was inactivated by addition of complete medium (2 mL). Cells were collected by centrifugation at 100 x g and the pellet was washed twice with cold PBS and then resuspended in 1 mL of annexin-binding buffer. 100 µL of the cell suspension was transferred to 1.5 mL eppendorf tube and 5 μl of FITC-conjugated annexin V and 5 μl of PI was added and incubated in dark for 15 min at room temperature. After 15 min incubation 400 µL of annexin binding buffer was added to the cells and the fluorescence was measured using BD accuri TM instrument flow cytometry.
The instrument was set for FL1 (annexin V-FITC) vs FL3 (PI) bivariant analysis. Data from 10,000 cells/sample was collected and dot plots of FL1 vs FL3 were generated. The quadrants were set based on the population of healthy, unstained cells in untreated samples compared to cells treated with a known apoptotic inducer camptothecin (5 μM) for 24 h. BD CSampler TM software was used to calculate the percentage of the cells in the respective quadrants. The experiment was performed in triplicate.
